Senores Pharmaceuticals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter
Senores Pharmaceuticals Ltd · Others (Uncategorized) · 29 Oct 2026, 10:58 pm
Senores Pharmaceuticals Reports Nil Deviation in IPO Proceeds Utilization for Sep'26 Quarter Senores Pharmaceuticals confirmed zero deviation in utilizing its ₹500.00 crore IPO proceeds for the quarter ended 30th Sep'26, as per SEBI Regulation 32. Out of the ₹500.00 crore raised, total funds utilized reached ₹418.83 crore. Key deployments include inorganic growth and corporate purposes (₹161.91 crore), debt repayment (₹93.30 crore), and working capital (₹102.74 crore). Fund allocations adhere to objects approved via prospectus and the 3rd Aug'26 postal ballot, with oversight from monitoring agency CARE Ratings.
Original exchange filing (PDF)
More announcements from Senores Pharmaceuticals Ltd
- We are pleased to announce that the manufacturing facility of our Subsidiary Company., Ratnatris Pharmaceuticals Private Limited has been awarded with the prestigious PIC/S GMP certification .... · 18 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding transcript of earnings conference call held on October 29, 2026 · 05 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 2026 · 30 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible .... · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Monitoring Agency report for the quarter ended September 30, 2026 · 29 Oct 2026
- We enclose herewith the Investor Presentation for Q2 & H1FY27 · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Appointment of joint Statutory Auditor of the Company · 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding media release · 29 Oct 2026
